Previous 10 | Next 10 |
BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will be reporting financial results for the sec...
2023-06-23 12:32:02 ET Summary The new drug application submission of mavorixafor for the treatment of patients with WHIM syndrome is expected in the 2nd half of 2023. Results from an ongoing phase 2 study using mavorixafor for idiopathic, cyclic, or congenital chronic neutropenia...
2023-06-13 11:54:01 ET X4 Pharmaceuticals ( NASDAQ: XFOR ) said on Tuesday it expects to join the Russell 3000 Index at the end of the 2023 Russell indexes annual reconstitution, effective June 26, 2023. XFOR shares jump +8.2% . Press Release For further deta...
BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with rare diseases of the immune system, today announced that it expects to be added to the broad-market Russell 30...
~60% reduction in annualized infection rate seen in the mavorixafor arm vs. placebo (p<0.01) >75% reduction in the percentage of individuals experiencing severe infections (Grade 3 or higher) in the mavorixafor group vs. placebo group >70% reduction in...
2023-05-16 08:56:24 ET X4 Pharmaceuticals ( NASDAQ: XFOR ) has agreed to sell an aggregate of ~42.78M shares to certain institutional accredited investors in a private investment in public equity financing. X4 anticipates that gross proceeds from the PIPE will be ~$65M. ...
BOSTON, May 16, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel small molecule therapeutics to benefit people with rare diseases of the immune system, today announced that it has agreed to sell an aggregate of 42,784,203 sha...
2023-05-06 19:35:09 ET X4 Pharmaceuticals, Inc. (XFOR) Q1 2023 Results Conference Call May 04, 2023 08:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Dr. Paula Ragan - President and CEO Adam Mostafa - CFO Mark Baldry - Chief Commercial Officer...
2023-05-04 06:15:21 ET X4 Pharmaceuticals press release ( NASDAQ: XFOR ): Q1 GAAP EPS of -$0.16 beats by $0.05 . X4 had $94.4 million in cash, cash equivalents, and restricted cash as of March 31, 2023. X4 believes that it has sufficient funds to support company operat...
Company to host webinar event on May 16 th presenting new clinical data from the 4WHIM Phase 3 trial; oral presentation to follow on May 21 st at the 2023 Clinical Immunology Society (CIS) Annual Meeting U.S. NDA submission of mavorixafor for WHIM s...
News, Short Squeeze, Breakout and More Instantly...
X4 Pharmaceuticals Inc. Company Name:
XFOR Stock Symbol:
NYSE Market:
X4 Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date Durable mean ANC levels above the lower limit of normal for CN were achieved for partic...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host a virtual investor event on Thursday, June 27, 2024 at 8:00 am ET. To register for the eve...